0001209191-23-043445.txt : 20230726 0001209191-23-043445.hdr.sgml : 20230726 20230726171004 ACCESSION NUMBER: 0001209191-23-043445 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230724 FILED AS OF DATE: 20230726 DATE AS OF CHANGE: 20230726 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mordwinkin Nicholas Michael CENTRAL INDEX KEY: 0001937229 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38542 FILM NUMBER: 231114402 MAIL ADDRESS: STREET 1: C/O KEZAR LIFE SCIENCES, INC. STREET 2: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kezar Life Sciences, Inc. CENTRAL INDEX KEY: 0001645666 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473366145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-822-5600 MAIL ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-07-24 0 0001645666 Kezar Life Sciences, Inc. KZR 0001937229 Mordwinkin Nicholas Michael C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Business Officer 0 Employee Stock Option (right to buy) 6.84 2023-07-24 4 D 0 185000 D 2033-01-07 Common Stock 185000 0 D Employee Stock Option (right to buy) 2.28 2023-07-24 4 A 0 185000 A 2033-01-07 Common Stock 185000 185000 D Employee Stock Option (right to buy) 2.28 2023-07-24 4 A 0 100000 0.00 A 2033-07-23 Common Stock 100000 100000 D One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date. On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. Twenty-five percent (25%) of the shares subject to the option shall vest on July 24, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such vesting date. /s/ Marc Belsky, Attorney-in-Fact 2023-07-26